With OpenAI's latest updates to its Responses API — the application programming interface that allows developers on OpenAI's platform to access multiple agentic tools like web search and file search ...

Running the same 12 prompts 100 times shows how inconsistent ChatGPT brand recommendations are – and why AI visibility ...

Dan tested Codex 5.3 on Proof, a macOS markdown editor that he's been vibe coding that tracks the origin of every piece of text—whether it was written by a human or generated by AI—and lets users ...

Marc Santos is a Guides Staff Writer from the Philippines with a BA in Communication Arts and over six years of experience in writing gaming news and guides. He plays just about everything, from ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...

The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted ...

We may earn a commission when you click links to retailers and purchase goods. More info. Checking complete transaction history for Google Wallet means taking a trip to the website, with history ...

A June 2025 clip of Florida Governor Ron DeSantis discussing self-defense ahead of “No Kings” protests has been miscaptioned online as him defending the woman fatally shot by a U.S. immigration agent ...

As 2025 ends, tensions between China and Taiwan are higher — and more overt — than at any point in recent years, fueled by expanded U.S. military support for Taipei, increasingly bold warnings from ...

(RTTNews) - Corcept Therapeutics (CORT) on Wednesday said the U.S. Food and Drug Administration has issued a Complete Response Letter for the New Drug Application of relacorilant to treat hypertension ...

(RTTNews) - Sanofi (SNY, SAN.PA) announced that the U.S. Food and Drug Administration has issued a complete response letter (CRL) for the new drug application of tolebrutinib to treat non-relapsing ...